BIOMAT Database Logo BIOMAT Database Logo

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons. 2012

Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Early Development Services CEE, PRA International, Warszawa, Poland. MultanowskaAgnieszka@PRAIntl.com

BACKGROUND Adult and elderly subjects previously immunized with cell culture-derived (CCIV; Optaflu(®)) or egg-derived (TIV; Agrippal(®)) trivalent influenza vaccines were enrolled in two extension studies (E1 and E2) to evaluate safety and immunogenicity after revaccination with CCIV/TIV alone or in combination with concomitant pneumococcal vaccine (PV). METHODS Adults and elderly subjects (n = 2609) were randomized 1:1 in E1 and allocated 3:1 in E2 to receive CCIV/TIV. In E2, a subset of elderly subjects was randomized to receive CCIV/TIV, with or without PV. Adverse reactions were monitored for six months and immunogenicity was assessed by hemagglutination inhibition (HI) assay using CHMP criteria. RESULTS Overall, the safety profile of both vaccines was similar, no serious adverse events related to either vaccine occurred. Mild or moderate pain was the most commonly reported reaction. Reactogenicity was slightly higher in elderly subjects receiving CCIV/TIV concomitantly with PV [46% vs. 37%; p = non-significant (NS)]. Both vaccines met CHMP licensure criteria for adults and elderly subjects. With concomitant CCIV and PV, all three CHMP criteria were met for A/H1N1 and A/H3N2, whereas the B strain only met seroprotection and GMR criteria. CONCLUSIONS Safety and immunogenicity of CCIV was not influenced by the type of vaccine received previously or by concomitant PV administration.

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006385 Hemagglutination Inhibition Tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons.
January 1999, Vaccine,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine.
August 2023, Human vaccines & immunotherapeutics,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.
March 2010, BMC infectious diseases,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children.
January 2002, Vaccine,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
July 2017, Human vaccines & immunotherapeutics,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly.
April 2019, Open forum infectious diseases,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
July 2012, Vaccine,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.
November 2007, Vaccine,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture.
August 1998, Vaccine,
Agnieszka Szymczakiewicz-Multanowska, and Maria Lattanzi, and Allen Izu, and Daniela Casula, and Mariavittoria Sparacio, and Csaba Kovacs, and Nicola Groth
Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects.
February 2008, Immunity & ageing : I & A,
Copied contents to your clipboard!